University of Oulu

Valerio Izzi, Juho Lakkala, Raman Devarajan, Anni Kääriäinen, Jarkko Koivunen, Ritva Heljasvaara, Taina Pihlajaniemi, Pan-Cancer analysis of the expression and regulation of matrisome genes across 32 tumor types, Matrix Biology Plus, Volume 1, 2019, 100004, ISSN 2590-0285, https://doi.org/10.1016/j.mbplus.2019.04.001

Pan-Cancer analysis of the expression and regulation of matrisome genes across 32 tumor types

Saved in:
Author: Izzi, Valerio1; Lakkala, Juho1; Devarajan, Raman1;
Organizations: 1Oulu Center for Cell-Matrix Research and Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, University of Oulu, P.O. Box 5000, FIN-90014 Oulu, Finland
2Centre for Cancer Biomarkers (CCBIO), Department of Biomedicine, University of Bergen, N-5009 Bergen, Norway
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 2.9 MB)
Persistent link: http://urn.fi/urn:nbn:fi-fe2019121146728
Language: English
Published: Elsevier, 2019
Publish Date: 2019-12-11
Description:

Abstract

The microenvironment plays a central role in cancer, and neoplastic cells actively shape it to their needs by complex arrays of extracellular matrix (ECM) proteins, enzymes, cytokines and growth factors collectively referred to as the matrisome. Studies on the cancer matrisome have been performed for single or few neoplasms, but a more systematic analysis is still missing. Here we present a Pan-Cancer study of matrisome gene expression in 10,487 patients across 32 tumor types, supplemented with transcription factors (TFs) and driver genes/pathways regulating each tumor’s matrisome. We report on 919 TF-target pairs, either used specifically or shared across tumor types, and their prognostic significance, 40 master regulators, 31 overarching regulatory pathways and the potential for druggability with FDA-approved cancer drugs. These results provide a comprehensive transcriptional architecture of the cancer matrisome and suggest the need for development of specific matrisome-targeting approaches for future therapies.

see all

Series: Matrix biology plus
ISSN: 2590-0285
ISSN-E: 2590-0285
ISSN-L: 2590-0285
Volume: 1
Article number: 100004
DOI: 10.1016/j.mbplus.2019.04.001
OADOI: https://oadoi.org/10.1016/j.mbplus.2019.04.001
Type of Publication: A1 Journal article – refereed
Field of Science: 1182 Biochemistry, cell and molecular biology
1184 Genetics, developmental biology, physiology
3111 Biomedicine
3122 Cancers
Subjects:
Funding: This work was supported by funds from The Academy of Finland (grants 284605, 294617, and 308867), The Jane and Aatos Erkko Foundation, The Sigrid Jusélius Foundation, The Cancer Society of Finland, The Emil Aaltonen Foundation, and The Finnish Cultural Foundation.
Academy of Finland Grant Number: 284605
294617
308867
Detailed Information: 284605 (Academy of Finland Funding decision)
294617 (Academy of Finland Funding decision)
308867 (Academy of Finland Funding decision)
Copyright information: © 2019 University Of Oulu. Published by Elsevier B.V. This is an open access article under the CC BY license(http://creativecommons.org/licenses/by/4.0/).
  https://creativecommons.org/licenses/by/4.0/